ArticleNeurology. Genetics2025
Risk of Cardiac Disease in a Population-Based Cohort of Myotonic Dystrophy Type 1 and Type 2 in the United States.
Article in Neurology. Genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background and Objectives: Myotonic dystrophy type 1 and type 2 (DM1/DM2) are multisystemic disorders that may affect heart function in addition to the progressive skeletal muscle weakness and myotonia that occur. There are limited population-based studies on the prevalence and risks associated with cardiac symptoms in DM1 and DM2. Methods: Cardiac data were abstracted from the medical records of 429 individuals with DM1 and DM2 with a health care encounter between 2008 and 2019. The frequencies of cardiac arrhythmias and of cardiomyopathy were assessed along with relationships to demographic data and age at onset. Results: A total of 429 individuals from MD STARnet were included in the analyses, with 82.3% having DM1. Overall, cardiac arrhythmias were observed in 44.5% and cardiomyopathy in 9.1%. The risk of developing a cardiac arrhythmia was much higher in DM1 than in DM2. Repeat length was not a risk factor for the development of a cardiac arrhythmia. Developing DM1 in childhood or adulthood as opposed to congenital onset was a risk factor of both cardiac arrhythmia and cardiomyopathy in multivariable analysis. Discussion: This study confirms the increased risk of cardiac arrhythmias in individuals with DM and DM2 and identifies the development of cardiomyopathy as a low-frequency event. Notably, the risk of cardiac arrhythmias is particularly elevated in DM1. The study reaffirms the need for serial cardiac monitoring in individuals with DM1/DM2.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.